A
Alexander W. Wood
Researcher at Novartis
Publications - 3
Citations - 1270
Alexander W. Wood is an academic researcher from Novartis. The author has contributed to research in topics: Transactivation & Reporter gene. The author has an hindex of 3, co-authored 3 publications receiving 1213 citations.
Papers
More filters
Journal ArticleDOI
Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex
Maina Lepourcelet,Ying-Nan P. Chen,Huisheng Wang,Phillip Crews,Frank Petersen,Charles W. Bruseo,Alexander W. Wood,Ramesh A. Shivdasani,Ramesh A. Shivdasani +8 more
TL;DR: These compounds meet predicted criteria for disrupting Tcf/beta-catenin complexes and define a general standard to establish mechanism-based activity of small molecule inhibitors of this pathogenic protein-protein interaction.
Journal ArticleDOI
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway.
Andrew L. Kung,Sonya Zabludoff,Sonya Zabludoff,Steven J. Freedman,Steven J. Freedman,Elizabeth A. Tanner,Annelisa Vieira,Susan Cornell-Kennon,Jennifer Lee,Beqing Wang,Jamin Wang,Klaus Memmert,Hans Ulrich Naegeli,Frank Petersen,Michael J. Eck,Kenneth W. Bair,Alexander W. Wood,David M. Livingston +17 more
TL;DR: A therapeutic window for pharmacological attenuation of HIF activity is demonstrated and the feasibility of disrupting a signal transduction pathway by targeting the function of a transcriptional coactivator with a small molecule is established.
Journal ArticleDOI
N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
Remiszewski Stacy W,Lidia Sambucetti,Kenneth W. Bair,John Bontempo,David Cesarz,Nagarajan Chandramouli,Ru Chen,Min Cheung,Susan Cornell-Kennon,Karl Dean,George Diamantidis,Green Michael A,Kobporn Lulu Howell,Rina Kashi,Paul Kwon,Peter T Lassota,Mary S. Martin,Yin Mou,Lawrence Blas Perez,Sushil K. Sharma,Troy Smith,Eric Sorensen,Francis Taplin,Nancy Trogani,Richard William Versace,Heather Brownlee Walker,Susan Weltchek-Engler,Alexander W. Wood,and Arthur Wu,Peter Atadja +29 more
TL;DR: One compound, NVP-LAQ824, had significant dose-related activity in the HCT116 colon and A549 lung tumor models, high MTD, and low gross toxicity, and has entered human clinical trials in 2002.